In this episode of The Brainstorm, we delve into the groundbreaking advancements in gene editing, focusing on its potential to transform healthcare. We explore the shift from treating rare diseases to tackling common killers like cardiovascular disease, and discover how CRISPR technology is paving the way for a new era in medical treatment.
If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn’t mean we don’t have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we’re sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Wolf.financial, and sponsored by Public. Tune in every week as we react to the latest in innovation. Here and there we’ll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK’s quick takes on what’s going on in tech today.
Key Points From This Episode:
- CRISPR-based gene editing is moving from treating rare diseases to addressing common conditions like cardiovascular disease.
- The transition from ex vivo to in vivo gene editing could simplify treatment processes significantly.
- Lipid nanoparticle delivery is a key advancement enabling in vivo gene editing.
- The potential market for in vivo gene editing treatments is vast, with significant implications for healthcare costs and patient outcomes.
To learn more about WOLF: https://wolf.financial
To learn more about Public: https://public.com/
Relevant Links:
https://www.ark-invest.com/newsletters/issue-491
